Magenta Therapeutics, Inc. Uncategorized Contracts & Agreements

13 Contracts & Agreements
Recent Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Amendment to Offer Letter, dated September 11, 2023, by and between Dianthus Therapeutics OpCo, Inc. and Simrat Randhawa
Magenta Therapeutics, Inc.
Biotechnology
NY
2024
Description of the Registrant's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended
Magenta Therapeutics, Inc.
Biotechnology
2024
Amendment to Offer Letter, dated September 11, 2023, by and between OpCo and Edward Carr
Magenta Therapeutics, Inc.
Biotechnology
NY
2023
Amendment to Offer Letter, dated September 11, 2023, by and between OpCo and Ryan Savitz
Magenta Therapeutics, Inc.
Biotechnology
NY
2023
Amendment to Offer Letter, dated September 11, 2023, by and between OpCo and Marino Garcia
Magenta Therapeutics, Inc.
Biotechnology
NY
2023
Contingent Value Rights Agreement, dated September 11, 2023, by and between the Company and the Rights Agent
Magenta Therapeutics, Inc.
Biotechnology
DE
2023
Form of Contingent Value Rights Agreement
Magenta Therapeutics, Inc.
Biotechnology
DE
2023
Form of Lock-Up Agreement
Magenta Therapeutics, Inc.
Biotechnology
2023
Form of Magenta Support Agreement
Magenta Therapeutics, Inc.
Biotechnology
DE
2023
Form of Dianthus Support Agreement
Magenta Therapeutics, Inc.
Biotechnology
DE
2023
Description of Securities of the Registrant
Magenta Therapeutics, Inc.
Biotechnology
2020
Agreement, dated as of May 31, 2018, by and between the Registrant and The Richmond Group, Inc
Magenta Therapeutics, Inc.
Biotechnology
2018
Clinical Trial Agreement by and between Regents of the University of Minnesota and the Registrant, dated as of January 22, 2018
Magenta Therapeutics, Inc.
Biotechnology
MN
2018